<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01389245</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-0001</org_study_id>
    <nct_id>NCT01389245</nct_id>
  </id_info>
  <brief_title>Study on OsseoSpeed™ TX Implants in the Upper Jaw in a Chinese Population</brief_title>
  <official_title>An Open, Prospective, Multi-center Study to Evaluate the OsseoSpeed™ TX Implant With an Early Loading Protocol in Patients With Tooth Loss in the Posterior Maxilla. A 3-years Follow-up Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dentsply Sirona Implants</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dentsply Sirona Implants</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the clinical efficacy of OsseoSpeed™ TX implants
      in a Chinese population by evaluation of marginal bone level alteration, implant stability
      and implant survival in the posterior maxilla up to 3 years after loading. Hypothesis: Early
      loading of the posterior maxilla is a safe and predictable procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Marginal Bone Level Alteration</measure>
    <time_frame>Measured at implant loading and at the 3-year follow-up after implant loading.</time_frame>
    <description>Marginal bone level determined from radiographs and expressed as the distance from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal bone level expressed in millimeters at the 3-year follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Stable Implants</measure>
    <time_frame>Measured at the 3-year follow-up after implant loading.</time_frame>
    <description>Implant stability evaluated clinically/manually (recorded as stable yes/no).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Periimplant Mucosa Condition - By Assessment of PPD</measure>
    <time_frame>Measured at the 3-year follow-up after implant loading.</time_frame>
    <description>Condition of the periimplant mucosa by assessment of probing pocket depth (PPD).
Change in pocket depth expressed in millimeters at the 3-year follow-up visit, compared to values obtained at delivery of permanent restoration, i.e. loading (baseline).
Negative value = increased pocket depth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Survived Implants</measure>
    <time_frame>Measured at the 3-year follow-up after implant loading.</time_frame>
    <description>Implant survival rate evaluated by clinically and radiographically, counting the number of implants remaining in function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Plaque</measure>
    <time_frame>Measured at the 3-year follow-up after implant loading.</time_frame>
    <description>Occurence of plaque around the study implant. Presented as number of implants that show presence of plaque at time of the 3-year follow-up visit after implant loading.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Partially Edentulous Jaw</condition>
  <arm_group>
    <arm_group_label>OsseoSpeed™ TX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OsseoSpeed™ TX implants of lengths 8-17 mm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OsseoSpeed™ TX</intervention_name>
    <description>OsseoSpeed™ TX implants of lengths 8-17 mm</description>
    <arm_group_label>OsseoSpeed™ TX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Provision of informed consent

          2. Aged 20-75 years at enrollment

          3. History of edentulism in the posterior maxilla, Kennedy classes I or II, of at least
             four months. Last natural tooth in function is canine or first bicuspid.

          4. Neighboring tooth to the planned bridge must have natural root.

          5. Presence of natural teeth, partial prosthesis and/or implants in the opposite jaw in
             contact with the planned bridge.

          6. Deemed by the investigator to have adequate bone height and a bone width of minimum
             5.5 mm.

          7. Deemed by the investigator as likely to present an initially stable implant situation

        Exclusion criteria:

          1. Unlikely to be able to comply with study procedures, as judged by the investigator

          2. Earlier graft procedures in the study area

          3. Current need for pre-surgical bone or soft tissue augmentation in the planned implant
             area.

          4. Uncontrolled pathologic processes in the oral cavity

          5. Known or suspected current malignancy

          6. History of radiation therapy in the head and neck region

          7. History of chemotherapy within 5 years prior to surgery

          8. Systemic or local disease or condition that could compromise post-operative healing
             and/or osseointegration

          9. Uncontrolled diabetes mellitus

         10. Corticosteroids or any other medication that could influence post-operative healing
             and/or osseointegration

         11. Smoking more than 10 cigarettes/day

         12. Present alcohol and/or drug abuse

         13. Involvement in the planning and conduct of the study (applies to both Astra Tech staff
             and staff at the study site)

         14. Previous enrollment in the present study.

         15. Simultaneous participation in another clinical study or participation in a clinical
             study during the last 6 months.

         16. Subjects that are unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deng Feilong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Capital Medical University School of Stomatology, Centre of Oral Implantation</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guanghua School of Stomatology, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510055</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Prosthodontics, Nanjing Stomatology Hospital, Nanjing University</name>
      <address>
        <city>Nanjing</city>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 6, 2011</study_first_submitted>
  <study_first_submitted_qc>July 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2011</study_first_posted>
  <results_first_submitted>April 22, 2020</results_first_submitted>
  <results_first_submitted_qc>April 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 6, 2020</results_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Jaw, Edentulous</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OsseoSpeed™ TX</title>
          <description>OsseoSpeed™ TX implants of lengths 8-17 mm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis population = Per Protocol Population. I.e. Protocol deviators excluded, a total of 10 subjects with 24 implants.</population>
      <group_list>
        <group group_id="B1">
          <title>OsseoSpeed™ TX</title>
          <description>OsseoSpeed™ TX implants of lengths 8-17 mm</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Implants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Marginal Bone Level Alteration</title>
        <description>Marginal bone level determined from radiographs and expressed as the distance from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal bone level expressed in millimeters at the 3-year follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline).</description>
        <time_frame>Measured at implant loading and at the 3-year follow-up after implant loading.</time_frame>
        <population>36 subjects (86 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 27 subjects (66 implants). Eighteen of the radiographs were not possible to evaluate, giving an overall number of 19 subjects (48 implants) as basis for the 3-year Marginal Bone Level alteration analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX</title>
            <description>OsseoSpeed™ TX implants of lengths 8-17 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Marginal Bone Level Alteration</title>
          <description>Marginal bone level determined from radiographs and expressed as the distance from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal bone level expressed in millimeters at the 3-year follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline).</description>
          <population>36 subjects (86 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 27 subjects (66 implants). Eighteen of the radiographs were not possible to evaluate, giving an overall number of 19 subjects (48 implants) as basis for the 3-year Marginal Bone Level alteration analysis.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Stable Implants</title>
        <description>Implant stability evaluated clinically/manually (recorded as stable yes/no).</description>
        <time_frame>Measured at the 3-year follow-up after implant loading.</time_frame>
        <population>36 subjects (86 implants) completed the 3-year follow-up visit. Analysis of implant stability was performed on the all patients treated population.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX</title>
            <description>OsseoSpeed™ TX implants of lengths 8-17 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Stable Implants</title>
          <description>Implant stability evaluated clinically/manually (recorded as stable yes/no).</description>
          <population>36 subjects (86 implants) completed the 3-year follow-up visit. Analysis of implant stability was performed on the all patients treated population.</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Periimplant Mucosa Condition - By Assessment of PPD</title>
        <description>Condition of the periimplant mucosa by assessment of probing pocket depth (PPD).
Change in pocket depth expressed in millimeters at the 3-year follow-up visit, compared to values obtained at delivery of permanent restoration, i.e. loading (baseline).
Negative value = increased pocket depth.</description>
        <time_frame>Measured at the 3-year follow-up after implant loading.</time_frame>
        <population>36 subjects (86 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 27 subjects (66 implants). For two of those implants evaluation of PPD was not performed, giving 25 subjects (64 implants) as basis for the PPD analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX</title>
            <description>OsseoSpeed™ TX implants of lengths 8-17 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Periimplant Mucosa Condition - By Assessment of PPD</title>
          <description>Condition of the periimplant mucosa by assessment of probing pocket depth (PPD).
Change in pocket depth expressed in millimeters at the 3-year follow-up visit, compared to values obtained at delivery of permanent restoration, i.e. loading (baseline).
Negative value = increased pocket depth.</description>
          <population>36 subjects (86 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 27 subjects (66 implants). For two of those implants evaluation of PPD was not performed, giving 25 subjects (64 implants) as basis for the PPD analysis.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Survived Implants</title>
        <description>Implant survival rate evaluated by clinically and radiographically, counting the number of implants remaining in function.</description>
        <time_frame>Measured at the 3-year follow-up after implant loading.</time_frame>
        <population>All participants treated with at least one study implant.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX</title>
            <description>OsseoSpeed™ TX implants of lengths 8-17 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Survived Implants</title>
          <description>Implant survival rate evaluated by clinically and radiographically, counting the number of implants remaining in function.</description>
          <population>All participants treated with at least one study implant.</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Plaque</title>
        <description>Occurence of plaque around the study implant. Presented as number of implants that show presence of plaque at time of the 3-year follow-up visit after implant loading.</description>
        <time_frame>Measured at the 3-year follow-up after implant loading.</time_frame>
        <population>36 subjects (86 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 27 subjects (66 implants). Evaluation of plaque was not performed on two of those subjects, giving an overall number of 25 subjects (64 implants) as basis for the 3-year presence of plaque analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX</title>
            <description>OsseoSpeed™ TX implants of lengths 8-17 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Plaque</title>
          <description>Occurence of plaque around the study implant. Presented as number of implants that show presence of plaque at time of the 3-year follow-up visit after implant loading.</description>
          <population>36 subjects (86 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 27 subjects (66 implants). Evaluation of plaque was not performed on two of those subjects, giving an overall number of 25 subjects (64 implants) as basis for the 3-year presence of plaque analysis.</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>OsseoSpeed™ TX</title>
          <description>OsseoSpeed™ TX implants of lengths 8-17 mm</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Femur Neck Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of urinary bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Paralytic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Insufficient osseointegration of the implant during healing phase</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager Global Clinical Research</name_or_title>
      <organization>Dentsply Sirona Implants, Mölndal, SWEDEN</organization>
      <phone>0046313763500</phone>
      <email>ClinicalResearchMolndal@dentsplysirona.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

